tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JPMorgan Chase & Co. Ceases Substantial Holding in Clarity Pharmaceuticals

Story Highlights
  • JPMorgan Chase & Co. and affiliates no longer hold substantial shares in Clarity Pharmaceuticals.
  • The change affects Clarity Pharmaceuticals’ shareholder structure and market dynamics.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
JPMorgan Chase & Co. Ceases Substantial Holding in Clarity Pharmaceuticals

TipRanks Black Friday Sale

Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an update.

Clarity Pharmaceuticals Ltd. has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of November 19, 2025. This change involves the sale and purchase of ordinary securities by JPMorgan’s subsidiaries, impacting the company’s shareholder structure and potentially influencing its market dynamics.

The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Average Trading Volume: 2,633,460

Technical Sentiment Signal: Sell

Current Market Cap: A$1.33B

See more data about CU6 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1